SG11202112346WA - T cell manufacturing compositions and methods - Google Patents

T cell manufacturing compositions and methods

Info

Publication number
SG11202112346WA
SG11202112346WA SG11202112346WA SG11202112346WA SG11202112346WA SG 11202112346W A SG11202112346W A SG 11202112346WA SG 11202112346W A SG11202112346W A SG 11202112346WA SG 11202112346W A SG11202112346W A SG 11202112346WA SG 11202112346W A SG11202112346W A SG 11202112346WA
Authority
SG
Singapore
Prior art keywords
methods
cell manufacturing
manufacturing compositions
compositions
cell
Prior art date
Application number
SG11202112346WA
Other languages
English (en)
Inventor
Buuren Marit M Van
Divya Reddy Lenkala
Jessica Kohler
Flavian Duvalle Brown
Christina Murphy Kuksin
Den Berg Joost Huibert Van
Boer Renate De
Noor Bakker
Ton Schumacher
Original Assignee
Biontech Us Inc
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc, Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis filed Critical Biontech Us Inc
Publication of SG11202112346WA publication Critical patent/SG11202112346WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Moulding By Coating Moulds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
SG11202112346WA 2019-05-08 2020-05-07 T cell manufacturing compositions and methods SG11202112346WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845251P 2019-05-08 2019-05-08
PCT/US2020/031898 WO2020227546A1 (fr) 2019-05-08 2020-05-07 Compositions et procédés de production de lymphocytes t

Publications (1)

Publication Number Publication Date
SG11202112346WA true SG11202112346WA (en) 2021-12-30

Family

ID=73051205

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112346WA SG11202112346WA (en) 2019-05-08 2020-05-07 T cell manufacturing compositions and methods

Country Status (14)

Country Link
US (1) US20220280621A1 (fr)
EP (1) EP3965784A4 (fr)
JP (2) JP2022531474A (fr)
KR (1) KR20220044242A (fr)
CN (1) CN114096261A (fr)
AR (1) AR118859A1 (fr)
AU (1) AU2020268397A1 (fr)
BR (1) BR112021022363A2 (fr)
CA (1) CA3137037A1 (fr)
IL (1) IL287874A (fr)
MX (1) MX2021013608A (fr)
SG (1) SG11202112346WA (fr)
TW (2) TW202248419A (fr)
WO (1) WO2020227546A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
US20150010519A1 (en) 2012-02-09 2015-01-08 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2017049291A1 (fr) 2015-09-18 2017-03-23 Baylor College Of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
US11948694B2 (en) * 2021-05-12 2024-04-02 Merative Us L.P. Controlling compartmental flows in epidemiological modeling based on mobility data
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc Preparations and methods for the production of T cells
WO2023159088A1 (fr) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions et procédés pour la multiplication des lymphocytes t spécifiques d'un antigène
WO2024124222A1 (fr) * 2022-12-09 2024-06-13 Biontech Us Inc. Compositions et procédés de production de lymphocytes t
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030196A2 (fr) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Procedes de traitement de maladies auto-immunes utilisant l'interleukine-21
WO2006110582A1 (fr) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions et methodes de traitement des brulures et de la sepsie
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
DE13746292T1 (de) * 2012-02-10 2014-10-30 Hakushinkouseikai Foundation Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen
WO2017026389A1 (fr) * 2015-08-10 2017-02-16 東レ株式会社 Inducteur de la réponse immunitaire
US10221249B2 (en) * 2015-09-10 2019-03-05 Affigen, Llc Method of making patient specific anti-idiotype antibodies
CN108473956B (zh) * 2015-10-09 2022-04-05 北昊干细胞与再生医学研究院有限公司 增强外源性施用t细胞的体内持久性和功效的方法、基因修饰的t细胞和方法以及使用方法
AU2018337960A1 (en) * 2017-09-20 2020-04-30 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
CA3081840A1 (fr) * 2017-11-08 2019-05-16 Neon Therapeutics, Inc. Compositions et procedes de production de lymphocytes t

Also Published As

Publication number Publication date
US20220280621A1 (en) 2022-09-08
EP3965784A4 (fr) 2023-06-21
EP3965784A1 (fr) 2022-03-16
TW202108761A (zh) 2021-03-01
TW202248419A (zh) 2022-12-16
AR118859A1 (es) 2021-11-03
AU2020268397A1 (en) 2022-01-06
CA3137037A1 (fr) 2020-11-12
CN114096261A (zh) 2022-02-25
IL287874A (en) 2022-01-01
JP2024038503A (ja) 2024-03-19
TWI777160B (zh) 2022-09-11
MX2021013608A (es) 2022-01-31
WO2020227546A1 (fr) 2020-11-12
JP2022531474A (ja) 2022-07-06
BR112021022363A2 (pt) 2022-03-22
KR20220044242A (ko) 2022-04-07

Similar Documents

Publication Publication Date Title
SG11202004116QA (en) T cell manufacturing compositions and methods
IL282735A (en) Preparations and methods for t-cell engineering
IL287874A (en) Preparations and methods for producing t cells
IL280134A (en) Anti-CD112R preparations and methods
SG11202113247VA (en) Methods for manufacturing t cells by direct sorting and compositions thereof
IL269334A (en) Improved compositions of t cells and methods
EP3776601A4 (fr) Compositions et procédés de fabrication d'électrode
IL291622A (en) Compositions comprising regulatory t cells and methods of making and using them
IL286776A (en) Preparations and methods for preparing t cell preparations and their uses
EP3813856A4 (fr) Compositions de cellules et leurs utilisations
GB201818084D0 (en) Compositions and methods
GB202208953D0 (en) Therapeutic cell compositions and methods for manufacture and uses thereof
GB202017593D0 (en) Compositions and methods and uses relating thereto
IL282160A (en) Preparations and methods for transferring genes between cells
IL288544A (en) Materials and methods for additive manufacturing
EP3810152A4 (fr) Méthodes et compositions de protection cellulaire
GB201904971D0 (en) Cell
GB201819987D0 (en) Methods and compositions
GB201817444D0 (en) Methods and compositions
GB201906202D0 (en) Cell
EP4048783C0 (fr) Cellule modifiée
SG11202108262VA (en) Bacterialcidal methods and compositions
IL312121A (en) Preparations and methods for the production of T cells
GB2586313B (en) Compositions and methods and uses relating thereto
IL289564A (en) Modified cells and related methods